169 related articles for article (PubMed ID: 38236515)
1. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Feuerstadt P; Allegretti JR; Dubberke ER; Guo A; Harvey A; Yang M; Garcia-Horton V; Fillbrunn M; Tillotson G; Bancke LL; LaPlante K; Garey KW; Khanna S
Infect Dis Ther; 2024 Jan; 13(1):221-236. PubMed ID: 38236515
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent
Garey KW; Dubberke ER; Guo A; Harvey A; Yang M; García-Horton V; Fillbrunn M; Wang H; Tillotson GS; Bancke LL; Feuerstadt P
Open Forum Infect Dis; 2023 Aug; 10(8):ofad383. PubMed ID: 37564743
[TBL] [Abstract][Full Text] [Related]
3. Safety of fecal microbiota, live-jslm (REBYOTA
Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
[TBL] [Abstract][Full Text] [Related]
4. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
J Clin Gastroenterol; 2023 Nov; ():. PubMed ID: 38019088
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
6. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
8. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
9. Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA
Knapple WL; Yoho DS; Sheh A; Thul J; Feuerstadt P
Therap Adv Gastroenterol; 2024; 17():17562848241239547. PubMed ID: 38529070
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA
Feuerstadt P; Harvey A; Yoho DS; Garcia-Diaz JB; Knapple WL; Bancke L
Open Forum Infect Dis; 2023 May; 10(5):ofad171. PubMed ID: 37256213
[TBL] [Abstract][Full Text] [Related]
11. Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial.
Lapin B; Garey KW; Wu H; Pham SV; Huang SP; Reese PR; Wang E; Deshpande A
Clin Infect Dis; 2023 Feb; 76(3):e1195-e1201. PubMed ID: 35789381
[TBL] [Abstract][Full Text] [Related]
12. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Berenson CS; Lashner B; Korman LY; Hohmann E; Deshpande A; Louie TJ; Sims M; Pardi D; Kraft CS; Wang EEL; Cohen SH; Feuerstadt P; Oneto C; Misra B; Pullman J; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Lee CH
Clin Infect Dis; 2023 Nov; 77(11):1504-1510. PubMed ID: 37539715
[TBL] [Abstract][Full Text] [Related]
15. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
16. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
17. Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent
Feuerstadt P; Oneto C; Tillotson G; Van Hise NW
Patient Prefer Adherence; 2023; 17():2153-2159. PubMed ID: 37667688
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection.
Hunt A; Drwiega E; Wang Y; Danziger L
Am J Health Syst Pharm; 2024 Mar; ():. PubMed ID: 38470061
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial.
Garey KW; Jo J; Gonzales-Luna AJ; Lapin B; Deshpande A; Wang E; Hasson B; Pham SV; Huang SP; Reese PR; Wu H; Hohmann E; Feuerstadt P; Oneto C; Berenson CS; Lee C; McGovern B; vonMoltke L
JAMA Netw Open; 2023 Jan; 6(1):e2253570. PubMed ID: 36716031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
